The RAS/RAF mitogen-activated protein kinase pathway (MAPK) is highly active in many tumor types including the majority of high-grade gliomas and expression of activated RAS or RAF in neural progenitor cells combined with either AKT activation or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo. This strongly suggests that this pathway is necessary for glioma formation and maintenance. To further define the role of this pathway in the development of high-grade gliomas, we used the established RCAS/TVA glioma mouse model to test the ability of activated MAPK/ extracellular signal-regulated kinase (ERK) kinase (MEK), a RAF effector, to induce tumors in vivo in the context of activated AKT or Ink4a/Arf loss. Although expression of activated MEK alone in neural progenitor cells is not sufficient for tumorigenesis, the combination of activated MEK and AKT or MEK with Ink4a/Arf loss is transforming. The data reveal that activation of the classical RAS/MAPK pathway, which is mediated through MEK, leads to the development of high-grade gliomas in vivo and suggest that MEK may be a relevant target for glioma therapy. To test this, we treated both mouse and human glioma cells with the MEK inhibitor PD0325901. Although this treatment induced apoptosis in a significant percentage of the cells, the effect was enhanced by combined treatment with the phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor NVP-BEZ235. Our results demonstrate that combined inhibition of MEK and PI3K/mTOR is a rational strategy for the treatment of high-grade gliomas and may be an effective adjuvant therapy for this disease.
Introduction
The current standard of care for patients with high-grade gliomas includes surgical resection followed by adjuvant radiotherapy and/or temozolomide chemotherapy. This treatment regimen increases the median survival of patients with high-grade gliomas from 12.1 to 14.6 months and was also found to significantly increase two-year survival to 27.2% compared with 10.9% for radiotherapy alone (Stupp et al., 2009) ; however, more effective treatment strategies are badly needed because the majority of patients experience tumor recurrence and ultimately succumb to the disease (Stupp et al., 2009) . Research in glioma therapy has recently shifted towards targeting the specific molecular alterations that underlie the pathogenesis of these cancers. Mutations or other genetic alterations in oncogenes or tumor suppressor genes often cause deregulation of signal transduction pathways, but determining which of these can be effectively targeted remains to be defined.
Alterations in receptor tyrosine kinase growth factor receptors (EGFR, PDGFR, MET and ERBB2), which result in constitutive downstream signaling of the classical mitogen-activated protein kinase (MAPK) (for example, RAS/RAF/MEK (MAPK signal-regulated kinase)/ERK (extracellular signal-regulated kinase)) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways, are found in almost all World Health Organization grade II, III and IV astrocytomas. The MAPK pathway is also activated in the majority of World Health Organization grade I tumors as a result of BRAF alterations . Together these data suggest that MAPK signaling is important for glioma development. Activation of the this pathway leads to cell-cycle progression through Cyclin D1 activation (Furnari et al., 2007) and inhibition of apoptosis by regulation of BCL-2-family member gene expression and activity (Balmanno and Cook, 2009) .
The majority of gliomas also have homozygous deletions that functionally inactivate the CDKN2A (cyclin-dependent kinase inhibitor 2A) locus (Ichimura et al., 1996) . This locus encodes two independent protein products, p16
INK4a and p14 ARF (reviewed in (Chin et al., 1998; Roussel, 1999) ). p16
INK4a is a specific inhibitor of Cyclin D/CDK4 or CDK6 complexes (Serrano et al., 1993) . By inhibiting the kinase activity of CDK4 and CDK6, p16 INK4a blocks retinoblastoma (RB) phosphorylation and prevents progression from G 1 to S in the cell cycle (Chin et al., 1998) . p14 ARF (p19 Arf in mice) (Quelle et al., 1995) stabilizes TP53 levels (Chin et al., 1998) and induces cell-cycle arrest in G1 and G2 in response to oncogenic stimuli (Kamijo et al., 1997; Zhang et al., 1998) . Disruption of the TP53 and RB pathways also occurs in gliomas through direct mutation or deletion of TP53 and RB, or amplification of HDM2 or CDK4, respectively (Parsons et al., 2008) .
Astrocytic gliomas typically contain inactivating mutations in the AKT signaling repressor, phosphatase and tensin homolog deleted on chromosome ten (PTEN). PTEN is a phosphatase that functions to inhibit the PI3K/AKT/mTOR pathway (Jiang et al., 1999) . In the absence of PTEN, levels of active AKT are elevated (Holland et al., 2000) . This signaling leads to progression through the cell cycle, increased proliferation and inhibition of apoptosis. AKT activation has also been documented in gliomas as a result of AKT amplification and increased PI3K activity due to mutations within either the regulatory subunit PIK3RI or the catalytic subunit PIK3CA (TCGA, 2008) . AKT activation has been shown to mimic loss of Pten in the context of glioma development in mice (Hu et al., 2005) .
We and others have successfully used a somatic-cell gene delivery method based on the RCAS/TVA system to evaluate the role(s) of specific genes in glioma initiation, progression and maintenance. Expression of KRAS, CRAF or BRAF in neural progenitor cells in combination with constitutive AKT activation, Pten loss or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo (Holland et al., 2000; Uhrbom et al., 2002; Hu et al., 2005; Lyustikman et al., 2008; Robinson et al., 2010) . Although it has been widely accepted that MEK1 and MEK2 are downstream effectors of the RAF proteins, several studies have suggested that mammalian RAF proteins might have other substrates. These include, but are not limited to, NFkB, IkB, CDC25C, RB, BCL-2 and BAD (Wellbrock et al., 2004) . In addition, CRAF has also been demonstrated to be an effector of BRAF (Wan et al., 2004) . In this study, we further delineated the downstream effectors of RAS and RAF in glioma development for the purpose of identifying additional therapeutic targets. Expression of a constituently active human gain of function (GF) MEK1 mutant (MEK-GF) (Mansour et al., 1996) in combination with Ink4a/Arf loss or constitutive AKT activation led to the development of high-grade gliomas in this model. Although treatment with the MEK inhibitor PD0325901 induced apoptosis in the majority of human glioma cells tested, this effect was enhanced by combined treatment with the PI3K/mTOR inhibitor NVP-BEZ235. Our results demonstrate that combined inhibition of MEK and PI3K/ mTOR is a rational strategy for the treatment of highgrade gliomas and may be an effective adjuvant therapy for this disease. Figure 1a ) and demonstrated protein function through assessment of phosphorylated Erk 1/2 (P-Erk) and phosphorylated Akt (Supplementary Figure 1b) . N-TVA/Ink4a/Arf lox/lox astrocytes infected with viruses containing CRAF
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, BRAF V600E , MEK-GF or KRAS G12D in combination with CRE or AKT expression formed numerous colonies in soft agar demonstrating the ability of the mutants to induce anchorage-independent growth in immortalized astrocytes, a characteristic feature of transformation. mice were injected with the indicated viruses at birth. Censored survival data were analyzed using a log-rank test of the KaplanMeier estimate of survival. No tumors were detected during the experimental period (12 weeks) in mice injected with MEK-GF (n ¼ 14) or CRE (n ¼ 14) alone and it has previously been shown that no tumors form in mice injected with AKT alone (Holland et al., 2000) . There was no significant difference in survival between mice injected with viruses containing MEK-GF þ AKT (n ¼ 22) (small dashed line) or MEK-GF þ CRE (n ¼ 18) (solid black line); P ¼ 0.7; however, a significant difference in survival was observed between mice injected with MEK-GF þ AKT or MEK-GF þ CRE when compared with mice injected with either virus alone; P ¼ 0.002. Immunophenotyping of these tumors showed variable expression of the glial marker glial fibrillary acidic protein (GFAP) and markers of glial phenotype that are also seen in human gliomas, such as MAP-2 (not shown), Olig-2 and doublecortin, but they were negative for the neuronal marker synaptophysin, which would be expected to be positive in primitive neuroectodermal tumors ( Figure 3 ). In conclusion, all tumors showed a glial phenotype with variable morphological resemblance to anaplastic astrocytomas, anaplastic oligodendrogliomas and glioblastomas ( Figure 2 ). No consistent correlation between the genotype (for example, CRE/AKT) and the presence of a specific cellular or architectural feature, necrosis, vascular endothelial proliferation or infiltration was seen. The immunophenotype, although showing some variability, confirmed the range of differentiation across both genotypes.
Glioma cells exhibit variable sensitivity to MEK and PI3K/mTOR inhibition
Using a genetic approach we previously demonstrated that tumors induced with KRAS are reliant on continued KRAS signaling for tumor maintenance in the context of activated AKT (Holmen and Williams, 2005) . In this study, we used a pharmacological . The ability of PD0325901 to induce apoptosis was reduced in N-TVA/Ink4a/Arf lox/lox astrocytes infected with viruses containing KRAS G12D or active AKT (Figure 4) . To determine the effect of combined inhibition of MEK and AKT signaling, the same cell lines were treated with 0.5 mmol/l NVP-BEZ235, a dual PI3K/mTOR inhibitor, alone or in combination with PD0325901. Interestingly, treatment with NVP-BEZ235 exhibited significant single agent activity with B30% cell death in N-TVA/Ink4a/ Arf lox/lox astrocytes infected only with a virus containing CRE. N-TVA/Ink4a/Arf lox/lox astrocytes transformed with KRAS G12D and CRE or CRAF D22W and AKT were the only other cells that were significantly more sensitive to treatment with NVP-BEZ235 than PD0325901 (Figure 4) . The combination of PD0325901 and NVP-BEZ235 significantly increased apoptosis in the entire panel of cell lines tested with the exception of KRAS G12D /CRE and CRAF D22W /AKT. The enhanced activity was most prominent in N-TVA/Ink4a/Arf lox/lox astrocytes infected with viruses containing KRAS and AKT. Treatment of these cells with PD0325901 or NVP-BEZ235 alone resulted in less than 5% apoptosis, whereas inhibition of both pathways resulted in 430% apoptosis (Figure 4) . Importantly, treatment with PD0325901 and NVP-BEZ235 alone or in combination did not induce significant apoptosis in primary uninfected mouse N-TVA/Ink4a/Arf lox/lox astrocytes (Figure 4 ).
MEK and PI3K/mTOR inhibition induces variable apoptosis in human glioma cell lines
To evaluate the role of RAS/MAPK signaling in human glioma maintenance, we treated 12 glioma cell lines and normal human astrocytes (HA) with PD0325901. Single-dose treatment of 1 mmol/l resulted in complete ERK inactivation for the experimental duration as measured by western blot for phosphorylated ERK (Supplementary Figure 4) and resulted in varying apoptotic responses after 48 h (Figure 5a ). Although no increase in apoptosis was detected in normal HA, treatment with PD0325901 was most effective at inducing apoptosis in LN229 cells and least effective at inducing apoptosis in U-118 cells (Figures 5a and b) . Phosphorylated ERK levels correlated with apoptotic response to PD0325901 in LN229, which was the most sensitive and had the highest levels of P-ERK, and U-118, which was the most resistant and had the lowest P-ERK levels ( Figure 5b) ; however, this effect was not consistent in the majority of the cell lines. Interestingly, cell lines possessing intact PTEN were more responsive to single agent MEK inhibition as a group compared with cell lines lacking PTEN. To investigate if targeting the RAS/MAPK and PI3K/mTOR signaling pathways simultaneously would increase cell death, we treated the panel of 12 glioma cell lines with 1 mmol/l PD0325901, 1 mmol/l NVP-BEZ235 or 1 mmol/l NVP-BEZ235 in combination with 1 mmol/l PD0325901. We observed significant AKT and ERK inhibition after 48 h as verified by western blot (Supplementary Figure 4) . Importantly, enhanced cell death was observed in nearly all of the glioma cell lines when these inhibitors were used in combination regardless of PTEN status, and no significant effect was observed on the level of apoptosis in primary HA (Figure 5a ). To assess whether the increase in apoptosis following the combined therapy was synergistic, additive or antagonistic, we treated two cell lines containing wild-type PTEN (LN18 and SF268) and two cell lines containing known PTEN mutations (SF539 and U251) with 1 mmol/l PD0325901 and 1 mmol/l NVP-BEZ235 alone or in combination for 72 h (Supplementary Figure 5) . The treatments were performed in at least quadruplicate to ensure that the statistical findings would be accurate and reliable. The test for the interaction term was statistically significant in cell lines LN18 (Po0.001), SF268 (P ¼ 0.003) and U251 (Po0.001), indicating departure from additivity; however, additivity between NVP-BEZ235 and PD0325901 was not statistically significantly rejected in cell line SF539 (P ¼ 0.215). The combination effect was calculated for cell lines LN18, U251 and SF268, and results showed that the apoptotic effect of the combination of PD0325901 and NVP-BEZ235 was synergistic (Supplementary Figure 5) . The degree of synergy was stronger in LN18 and U251 as compared with SF268.
A negative-feedback loop exists between MEK and PI3K signaling Following treatment with PD0325901, we observed increased AKT phosphorylation in several of the cell lines analyzed. Increased ERK phosphorylation was also observed in several of the cell lines evaluated upon administration of NVP-BEZ235 (Supplementary Figure 4) . We confirmed these findings using an additional MEK inhibitor, U0126, demonstrating that this phenomenon is not the result of off-target effects of one drug. In 10% serum, this effect could not be completely abolished through inhibition of both pathways (Supplementary Figure 6) ; however, we found that in 2% serum activation of AKT by MEK inhibition and activation of ERK by PI3K/mTOR inhibition was abolished by treatment with both NVP-BEZ235 and PD0325901 (Supplementary Figure 4) .
MEK and PI3K/mTOR inhibition is more effective than temozolomide at inducing cell death in human glioma cells Chemotherapeutic use of temozolomide requires a prolonged treatment to allow for a build up of DNA adducts and a number of different temozolomide regimens and dosing schedules have been described (Newlands et al., 1997; Stupp et al., 2009) . To assess whether combined MEK and PI3K/mTOR inhibition is equally or more effective in inducing cell death than temozolomide, the 12 glioma cell-line panel and normal HA were treated with 200 mmol/l temozolomide for 7 days (Beier et al., 2008) . To provide a direct comparison, we also treated the same panel of glioma cell lines with (a) Apoptotic sensitivity of normal human astrocytes (HA) and glioma cell lines to treatment with 1 mmol/l PD0325901 (901), 1 mmol/l NVP-BEZ235 (BEZ) or both (BEZ/901) in combination for 48 h. Cells were treated in triplicate and DMSO-treated samples served as controls. Apoptosis was quantitated using the Guava Nexin assay using a Guava EasyCyte flow cytometer. Data were normalized to the controls and are represented as mean±s.e.m. Cell lines are grouped according to PTEN mutation status. (b) Phosphorylated ERK levels correlate with apoptotic response to PD0325901. LN-229 and U-118 cells were treated with 1 mmol/l PD0325901 for 48 h followed by assessment of apoptosis using the Guava Nexin assay using a Guava EasyCyte flow cytometer. Cells staining positive for both Annexin V and 7-AAD represent apoptotic cells and are in the upper right quadrant. The numbers in the upper right quadrant reflect the percentage of cells that have undergone apoptosis. Western-blot analysis of treated LN-229 and U-118 cells was used to assess phosphorylated and total ERK levels. Blots were re-probed with a-tubulin to confirm equal loading. levels of cell death at 94 and 83%, respectively. U373 was the most resistant at B40% cell death. Importantly, less than 20% cell death was observed following treatment with the combined therapy in the normal HA ( Figure 6 ).
Discussion
High-grade gliomas have been found to possess multiple genetic abnormalities. Incorporation of genomic analyses into major signaling pathways implicated in this disease revealed alterations in three major pathways encompassing receptor tyrosine kinase signaling to RAS/PI3K/AKT and the tumor suppressor pathways linked to TP53 and RB. Receptor tyrosine kinase/RAS/ PI3K signaling was altered in 88%, the TP53 pathway was altered in 87%, and the RB pathway was altered in 78% of the samples analyzed. Interestingly, 74% of tumor samples had alterations in all three pathways, further highlighting their importance in high-grade gliomas (TCGA, 2008) ; however, the key elements that are required for continued tumor growth and maintenance remain to be defined such that more effective therapies can be designed. We previously demonstrated that expression of BRAF V600E in cooperation with activation of AKT or loss of the Ink4a/Arf tumor suppressor genes can generate high-grade gliomas in mice (Robinson et al., 2010) . In this study, we have evaluated signaling downstream of BRAF and observed that activated MEK, a RAF effector, is capable of inducing high-grade gliomas in the same context. These data reveal that activation of the classical RAS/MAPK pathway, which is mediated through RAF and MEK, is critical for the development of high-grade gliomas.
Four molecular subtypes of gliomas have recently been classified based on gene expression signatures. These include Classical, Mesenchymal, Proneural and Neural (Brennan et al., 2009; Verhaak et al., 2010) . MEK-induced tumors most closely reflect the Classical and Proneural subtypes, which display the highest activity of the PI3K and MAPK pathways; however, it should be noted that elevated levels of both of these signaling pathways were detected in nearly all tumors analyzed (Brennan et al., 2009) . Behaviorally, the MEKinduced tumors were more invasive than the tumors arising from BRAF V600E expression in the context of Ink4a/Arf loss that we have previously described; the gliomas were most similar to those induced by KRAS
G12D
or BRAF V600E expression in the context of AKT activation (Robinson et al., 2010) . In contrast to the BRAF-driven tumors where clear differences were observed in the context of Ink4a/Arf loss or AKT activation, no distinguishing features defined the MEKdriven tumors in either context. These differences may instead result from either the infection of nestinexpressing cells committed to different lineages or variation in the level of expression of the delivered genes. The latency and incidence of the MEK-driven tumors was most similar to that observed with BRAF and AKT, BRAF and Cre, and KRAS and AKT. In contrast, both latency and incidence were significantly higher in tumors induced with KRAS and Cre (Robinson et al., 2010) .
Based on these findings, it is logical to assume that inhibition of the MAPK pathway alone or in combination with PI3K inhibition may be an effective strategy for the treatment of high-grade gliomas. A current challenge facing development of targeted therapies is selection of the appropriate patient population for clinical-trial evaluation. Combination therapy that targets common downstream mediators of growth factor signaling such as MEK, PI3K and mTOR should be effective in the Classical, Mesenchymal and Proneural glioma subtypes that harbor mutations in upstream signaling components. Many inhibitors targeting the RAS/MAPK-signaling pathway are currently in clinical trials, including inhibitors of RAS, RAF and MEK (Roberts and Der, 2007) . Two novel, orally bioavailable MEK inhibitors (PD0325901 and ARRY-142886) demonstrated increased potency against MEK (IC50: 1-10 nM) and had better biopharmaceutical properties including improved bioavailability, lower metabolic clearance and longer-lasting target suppression compared with first and second generation MEK inhibitors (Wang et al., 2007) . PD0325901 has shown promising preclinical activity in vitro and in vivo against a broad spectrum of tumors and objective patient responses have been reported in melanoma; however, neurotoxicity was observed in a subset of patients (LoRusso et al., 2010) . Although this effect might be considered detrimental for some tumor types, it is necessary and potentially beneficial for the treatment of brain metastases and gliomas. Importantly, NVP-BEZ235 has been shown to reduce PI3K signaling in an in vivo glioma model when administered orally (Liu et al., 2009) .
PI3K pathway activation is known to mediate resistance to MEK inhibitors in RAS mutant cancers (Wee et al., 2009 ) and accordingly we observed greater resistance to MEK inhibition in tumor cells with high levels of PI3K/ AKT signaling. Interestingly, we also observed negative regulatory feedback between MEK and AKT that amplify the signal and promote resistance to the inhibitors. This cross talk may explain why only moderate levels of cell death were observed with single-agent treatment. We found that combined inhibition of MEK and PI3K/ mTOR in low serum eliminated the cross talk and synergistically induced apoptosis in the majority of glioma cell lines tested. Importantly, the combination therapy did not significantly increase the level of apoptosis in normal human astrocyte controls but was more effective than temozolomide at inducing cell death in a large panel of human glioma cell lines. In addition to maximizing response, this combination may reduce or prevent the occurrence of both primary and acquired resistance, which remains a significant obstacle to the successful attainment of a targeted agents' therapeutic potential. Conversely, it is possible that this multi-targeted approach may produce unacceptable side effects that limit the therapeutic benefit of the combination. This will need to be determined empirically through additional in vivo studies. Our data clearly demonstrate the potential power of targeted molecular therapy for the treatment of glioma and highlights the necessity of targeting multiple growth pathways to induce apoptosis. Combined treatment with PD0325901 and NVP-BEZ235 has the potential to improve overall patient survival and progression-free survival compared with the current standard of care. Altogether these findings have important implications for the design of therapeutic strategies aimed at this disease.
Materials and methods
Transgenic mice
Nestin-TVA/Ink4a/Arf lox/lox mice have been described (Robinson et al., 2010) . All experiments were performed in compliance with the 'Care and Use of Animals' (Council et al., 1996) and were approved by the IACUC before experimentation.
Vector constructs
The retroviral vectors used in this study were replicationcompetent avian leukosis virus long-terminal repeat, splice acceptor and Bryan polymerase-containing vectors of envelope subgroup A (designated RCASBP(A)) (Federspiel and Hughes, 1997 (Holland et al., 2000; Holmen and Williams, 2005; Lyustikman et al., 2008; Robinson et al., 2010) . The N-terminus of KRAS has a FLAG epitope tag and AKT contains an HA epitope tag at the Cterminus (Holland et al., 2000) . A constitutively active MEK-GF lacking residues 32-51 (DN3) and with S218E and S222D substitutions has been described (Mansour et al., 1996) . Details regarding RCASBP(A)MEK-GF cloning are available upon request.
Cell culture DF-1 cells were maintained as described (Schaefer-Klein et al., 1998) . Primary mouse astrocytes have been described (Robinson et al., 2010) . Human glioma cell lines were maintained in RPMI with 5% fetal bovine serum and 1 Â penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Normal HAs were maintained in astrocyte media containing astrocyte growth supplement (ScienCell, Carlsbad, CA, USA) with 2% fetal bovine serum and 1 Â penicillin/streptomycin (Invitrogen).
Virus propagation and infection
Viral propagation and infection was performed as previously described (Robinson et al., 2010) .
Detection of RCASBP(A)MEK-GF integration
Detection of RCASBP(A)MEK-GF integration into the genome of the tumor cells was performed by PCR. Brain tissue from injected and control mice was paraffin embedded and 5-mm sections were adhered to glass slides. The location of the tumors on the slides was confirmed by histopathology on corresponding sections. The slides were de-waxed in xylene and rehydrated through graded alcohols. Tissue from the tumors was collected using a sterile needle and DNA was extracted using the Qiagen DNAeasy mini kit as per the manufacturer's specifications (Qiagen, Valencia, CA, USA). Details of the PCR are available upon request.
Western blotting
Western blotting was performed using standard procedures. Details regarding the specific antibodies used are provided in Supplementary information.
Immunohistochemistry
Dissected brains were fixed in 10% formalin, embedded in paraffin, cut into 5 mm sections and adhered to glass slides. The sections were stained with hematoxylin and eosin or left unstained for immunohistochemistry. All immunostaining was carried out using the Ventana Benchmark or Discoveryautomated staining apparatus (Ventana Medical Systems, Tuscon, AZ, USA) following the manufacturer's guidelines. Details regarding the specific antibodies used are provided in Supplementary information.
Drug treatments and cell viability
All cell viability assays were initiated 24 h post cell-line seeding and were carried out for the times indicated in media containing 2% serum. Single-treatment dosing of human and mouse astrocytes and glioma cell lines with PD0325901 (Selleck Chemicals, Houston, TX, USA), U0126 (Cell Signaling, Boston, MA, USA), and NVP-BEZ235 (Novartis, Groton, CT, USA) was based on titration studies (0-5 mmol/l) examining phospho-ERK and phospho-AKT levels. HAs and glioma cell lines were also treated with 200 mmol/l of temozolomide (Santa Cruz, Santa Cruz, CA, USA). Vehicle control samples were treated with an equal volume of dimethyl sulfoxide (DMSO). Cell death was quantitated using the Guava ViaCount assay (Guava Technologies, Hayward, CA, USA) and apoptosis was quantitated using the Guava Nexin Annexin V assay (Guava Technologies). The Nexin assay uses two dyes: 7-AAD, a cell impermeant dye, as an indicator of membrane structural integrity and Annexin V-PE to detect phosphatidylserine on the external membrane of apoptotic cells. Samples were prepared as per the manufacturer's specifications at the indicated time points and assayed promptly.
Statistical analysis
Censored survival data was analyzed using a log-rank test of the Kaplan-Meier estimate of survival for the n indicated. in vitro experiments were performed in duplicate unless otherwise stated and data are presented as the mean with s.e.m. To assess if combination therapy with PD0325901 and NVP-BEZ235 produced a synergistic response, direct measurements of apoptosis were obtained in replicates of 4-6 for each group. After log transformation, results were analyzed using analysis of variance techniques for 2 Â 2 factorial designs. The statistical significance of the interaction term was tested at the two-sided alpha ¼ 0.05 level to evaluate the additivity of the apoptotic effects of PD0325901 and NVP-BEZ235. Statistically-significant interaction terms indicate a departure from additivity and that the effect of the combination of PD0325901 and NVP-BEZ235 was either synergistic or antagonistic. For cell lines with statistically-significant interaction terms, the following calculation was made to assess the synergistic effect of the combination: S ¼ ð1 À A 901þBEZ Þ=ð1 À A 901 Þð1 À A BEZ Þ where A 901 , A BEZ and A 901 þ BEZ are the mean apoptotic values for PD0325901, NVP-BEZ235 and the combination, respectively. S is the combination effect, and values less than one indicate synergy, whereas values greater than one indicate antagonism (S ¼ 1, indicates additivity).
